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Abstract
Parkinson’s disease (PD) is histologically described by the deposition of α-synuclein,
whose accumulation in Lewy bodies causes dopaminergic neuronal death. Althoughmost
of PD cases are sporadic, point mutations of the gene encoding the α-synuclein protein
cause inherited forms of PD. There are currently six known point mutations that result in
familial PD. Oxidative stress and neuroinflammation have also been described as early
events associated with dopaminergic neuronal degeneration in PD. Though it is known that
microglia are activated by wild-type α-synuclein, little is known about its mutated forms and
the signaling cascades responsible for this microglial activation. The present study was
designed to investigate consequences of wild-type andmutant α-synuclein (A53T, A30P
and E46K) exposure on microglial reactivity. Interestingly, we described that α-synuclein-
inducedmicroglial reactivity appeared to be peptide-dependent. Indeed, the A53T protein
activated more strongly microglia than the wild-type α-synuclein and other mutants. This
A53T-induced microglial reactivity mechanismwas found to depend on phosphorylation
mechanismsmediated by MAPKs and on successive NFkB/AP-1/Nrf2 pathways activation.
These results suggest that the microgliosis intensity during PDmight depend on the type of
α-synuclein protein implicated. Indeed, mutated forms are more potent microglial stimula-
tors than wild-type α-synuclein. Based on these data, anti-inflammatoryand antioxidant
therapeutic strategiesmay be valid in order to reducemicrogliosis but also to subsequently
slow down PD progression, especially in familial cases.
Introduction
Parkinson’s disease (PD) is one of the most common neurodegenerative diseases. This age-
related disorder is clinically characterized by several motor symptoms such as bradykinesia,
resting tremor and muscular rigidity, but also by non-motor symptoms as depression, gastro-
intestinal features and dementia [1,2]. PD is histologically described by the deposition of a
physiological protein present in the brain, α-synuclein (α-syn). Its accumulation causes
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death of dopaminergic neurons resulting in the loss of the dopaminergic nigrostriatal path-
way [3].
Αlpha-synuclein, a 140 amino-acid protein, accounts for about 1% of the total cytosolic pro-
teins in brain. Its expression is highest in the dopaminergic neurons of the substantia nigra
pars compacta (SNpc) and is intracellularly localized in presynaptic terminals. Therefore, α-
syn might be involved in neurotransmitter release, synaptic vesicle trafficking, synaptic func-
tion and plasticity [4–7]. Alpha-synuclein proteins have the capacity to self-assemble, passing
from unfoldedmonomers to oligomeric species, and then to heavy aggregates (called amyloid
fibrils). The accumulation of these insoluble fibrils progressively promotes the formation of
intracellular inclusions called Lewy bodies [4] within neurons and glial cells [8,9]. Recent stud-
ies suggest that α-synuclein oligomers are able to bind to lipids, disrupting cellular membrane
integrity, and cause cell death both in vitro and in vivo [10–12]. Furthermore, it is known that
aggregated α-synuclein present in Lewy bodies induces microglial activation leading to the
death of dopaminergic neurons [13].
Although most of PD cases are sporadic, point mutations of Snca, the gene encoding the
α-syn protein, cause inherited forms of PD [14]. In the late 20th century, Polymeropoulos
et al. described the first disease-causingmutation in different Mediterranean families. The
substitution of alanine to threonine at position 53 of the α-syn protein (A53T) was identi-
fied as the cause of a severe autosomal dominant trait of Parkinsonism, characterized by an
early onset with a short disease duration to death (less than 10 years). Afterwards, two other
point mutations were identified, both responsible of dominant PD: A30P and E46K [15–
17]. More recently, three additional familial mutations A53E, G51D and H50Q were identi-
fied [18–20].
Since the beginning of the century, some clues have demonstrated that α-syn can be secreted
by cells and be present in biological fluids such as cerebrospinal fluid and blood plasma of both
PD and healthy patients [21–23]. This extracellularα-syn may be responsible for the initiation
and the maintenance of inflammatory events through the activation of microglia, the resident
macrophages of the brain [24–26]. Activated microglia adopt morphological changes from a
resting ramified shape to an amoeboid profile, accompanied by cell surface receptor impair-
ments, production of reactive oxygen species (ROS) and release of cytokines [27–29]. Activated
microglia phagocyte foreign antigens, proliferate and recruit additional microglial cells to
mediate the inflammatory response. Although this phenomenon is essential to fight against
infections or brain trauma, an over-activation can give rise to severe cellular damages and, in
case of PD, could contribute to dopaminergic neuron depletion. The high levels of tumor
necrosis factor alpha (TNFα) and interleukin-1beta (IL-1β) proteins assayed in the SNpc, stria-
tum, cerebrospinal fluid and peripheral bloodmononuclear cells from idiopathic patients rein-
force this hypothesis [30]. The CXCL10 chemokine, also known as interferon gamma-induced
protein 10 (IP-10), has also been found to be elevated in the CSF of brain patients and to be
linked to neurodegeneration [31]. These three key inflammatorymediators (TNFα, IL-1β and
CXCL10) have been described as markers associated with the microglial pro-inflammatory
phenotype [32,33]. Given the importance of neuroinflammation in the development of PD,
further studies are necessary to understand the precise role of α-synuclein in the microglial
reactivity.
Therefore, we investigated whether different α-synuclein proteins were able to activate
microglial cells and to promote subsequently a pro-inflammatory state. We provide a direct
demonstration that the magnitude of the reactive microgliosis is higher after an A53T exposure
compared to the wild-type protein or the other mutants. We also detail a large part of this
A53T-induced microglial reactivity mechanism.
A53T Protein Induces a StrongMicrogliosis
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Materials andMethods
Ethics Statement
All animal experiments were carried out according to the 2010/63/EU European Union Direc-
tive and internal ethical committee regulations. The protocol was approved by the Animal
Experimentation Ethics Committee (AEEC) of the University of Luxembourg. All efforts were
made to minimize suffering.Newbornmice were decapitated.
Cell cultures
Mixed glial cell cultures were prepared from newbornC57BL/6J mouse brains (Harlan, The
Netherlands) as previously described [34]. Cells were plated and grown in Dulbecco’s Modified
EagleMedium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin
and 100 μg/ml streptomycin at 37°C in a humidified atmosphere containing 5% CO2. The cul-
ture mediumwas changed after 3 days of culture. After 12-14 days, mixed glial cell cultures
had reached confluence.Microglia present in the astrocytemonolayer were collected by a posi-
tive selection using a magnetic cell sorting (MACS) approach, as previously described [34].
Cells were selected using an anti-CD11b antibody following the manufacturer’s instructions
(Miltenyi Biotec, The Netherlands). Finally, microglia were plated in a mix (1:1 v/v) of DMEM
and mixed glial cell culture-conditionedmedium at 37°C in a humidified atmosphere contain-
ing 5% CO2. Microglial cultures were treated 24 h later. Cell culture products were provided by
Invitrogen (Belgium).
Cell treatments
Purified recombinant human α-synucleins (wild-type and mutants proteins; AJ Roboscreen
GmbH, Germany) were initially resuspended in sterile water at a concentration of 100 μM and
stored at -20°C. Endotoxin contamination of the different α-synuclein aliquots was evaluated
by the commercial PYROGENT™ Plus Gel Clot LAL Single Test Vials (Lonza, Belgium).
Microglial cultures were exposed to wild-type and mutant purified recombinant α-synu-
cleins at a final concentration of 5 μM.Microglial cultures were also exposed to lipopolysaccha-
ride (LPS 055:B5 from Escherichia coli, Sigma, Belgium) at 1 ng/ml or to menadione (10 μM,
Sigma), a reactive oxygen generator. Cells were pre-treated for 1 h with 10 μM of MAPKs
inhibitors (inhibitors of p38 (SB203580), ERK (PD98059) or JNK (SP600125)) before A53T
treatment.
Characterizationof the different α-synuclein protein preparations
Wild-type and mutant α-synuclein proteins were characterized by gel electrophoresis. Sample
buffer containing no SDS or β-mercaptoethanol was added to the different α-synuclein prepa-
rations. Alpha-synuclein proteins (0.25 μg) were resolved on a 12% acryl/bis-acrylamidegel in
the absence of SDS (non-denaturating electrophoresis). All samples were electrophoresed
using a Tris-Glycine-SDS buffer. Proteins were transferred to a 0.45 μm nitrocellulosemem-
brane. The membrane was blocked in 3% (w/v) nonfat drymilk in phosphate-buffered saline
(pH 7.4) containing 0.1% (v/v) Tween 20 for 1 h at room temperature. The blot was incubated
overnight at 4°C with the 4D6 primary antibody (1:2000, Covance, USA), a mouse monoclonal
antibody specific to α-synuclein proteins. For revelation by chemiluminescence, a peroxydase-
conjugated anti-mouse antibody (Amersham Biosciences,UK) was applied at a 1:2000 dilution.
Antibody complexes were detected by using SuperSignalWest Femto Maximum Sensitivity
Substrate (Pierce, Belgium) on a ChemiDoc™XRS+ System (Bio-Rad, Belgium).
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Cellular viability assays
Mitochondrial functionwas assessed as an index of cellular viability using theMTTmethod.
This assay measures the ability of mitochondrial dehydrogenases to convert 3-[4,5-dimethylthia-
zol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) to colored insoluble formazan. Cells were
seeded in 48-well plates at an initial density of 1 x 105 cells/well. After treatment, cells were incu-
bated for 3 h at 37°C withMTT (0.35 mg/ml) diluted in PBS. Then, the mediumwas removed,
and cells were lysed by addition of DMSO. Absorbance was measured at 540 nm using a micro-
plate reader (TECAN, Austria). Viability was estimated from the absorbance of treated versus
untreated cells (100%).
Cell viability was also assessedwith a cytotoxicity detection kit (Roche Applied Science, Ger-
many) based on the measurement of LDH released from damaged cells. Cells were seeded on
48-well plates at an initial density of 1 x 105 cells/well. According to the manufacturer’s instruc-
tions, culture supernatants were sampled after treatments and incubated for up to 30 min at
room temperature with a freshly prepared reactionmixture (v/v). Absorbance was then deter-
mined at 490 nm using a microplate reader (TECAN). Viability was estimated from the absor-
bance of treated versus untreated cells (100%).
Immunocytochemistry
Microglial cells were plated on poly-L-lysine coated coverslips. After treatments, cells were
then fixed with paraformaldehyde (4% in PBS) for 20 min at room temperature, and permeabi-
lized for 5 min in PBS containing 0.3% Triton X100. Following 3 washings in PBS, the blocking
step was realized with 3% BSA in PBS at room temperature for 30 min. The cells were then
incubated overnight at 4°C with a rabbit anti-Iba1 (1:300, BiocareMedical, USA). After wash-
ing steps with PBS, cells were incubated with Alexa488-conjugated anti-rabbit (1:1000, Life
Technologies, Belgium) at room temperature for one hour. The cells were washed and
mounted with Dapi-Fluoromount G (SouthernBiotech,USA). Cells were observedunder a
LSM 510 META inverted confocal microscope (Carl ZeissMicro Imaging, Göttingen, Ger-
many) at a 40-fold magnification.
Real-Time reverse transcription-polymerase chain reaction (RT-PCR)
analysis
Total RNA was isolated frommicroglia using the innuPREP RNA Kits (Westburg, The Nether-
lands) according to the manufacturer’s protocol. Complementary DNA (cDNA) was synthe-
sized from RNA samples using the ImProm-II Reverse Transcription System (Promega, The
Netherlands). PCR analyses were performed on a Bio-Rad iCycler (iQ5 Real-Time PCR Detec-
tion System, Bio-Rad) using iQTM SYBR Green Supermix (Promega). Primer sequences
(Table 1) were designed using the BeaconDesigner Software (Bio-Rad). Gene expression was
analyzed using the comparative threshold cycle (Ct) method. The target gene was normalized
to the endogenous reference gene, Rpl27 (a housekeeping gene coding for a ribosomal protein).
The mRNA expression fold change was calculated using the expression 2-ddCt, where ddCt =
(Ct, target−Ct, Rpl27)treated sample−(Ct, target−Ct, Rpl27)control sample.
PCR arrays analysis
Mouse Cytokines and Chemokines PCR arrays (Qiagen, The Netherlands) were performed fol-
lowing the manufacturer’s instructions. Firstly, reverse transcription was performed following
the protocol detailed previously (RT-PCR analysis Section). Secondly, PCR components mix
was prepared by mixing complementary DNA with RT2 SYBR GreenMastermix. PCR arrays
A53T Protein Induces a StrongMicrogliosis
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analyses were performed on a Bio-Rad iCycler (iQ5 Real-Time PCR Detection System) using a
2-stage program provided by the manufacturer: 10 min at 95°C followed by 40 cycles, consist-
ing of denaturation at 95°C for 15 sec and annealing/extension at 60°C for 60 sec. Analysis of
gene expression was performed using the comparative threshold cycle (Ct) method.
Measurement of pro-inflammatorymediator releases
Cells were seeded on 12-well plates at an initial density of 7 x 105 cells/well. The production of
prostaglandins E2 (PGE2), TNFα and CXCL10 was measured in the culture medium after treat-
ments. PGE2 and TNFα / CXCL10 release was respectively measured by a commercially avail-
able Enzyme ImmunoAssay kit (Assay Designs, USA) and a sandwich Enzyme Linked
ImmunoSorbent Assay (R&D Systems, USA). Absorbance was then measured at 540 nm using
a microplate reader (TECAN).
Immunoblotting
Microglial cells were plated into 25 cm2 flasks. Total proteins were extracted with RIPA buffer
(Pierce) and 1% protease / phosphatase inhibitor cocktail (Pierce). Nuclear extracts were pre-
pared using a nuclear extract kit according to the manufacturer’s instructions (Active Motif,
CA). Protein content was determined using the Bio-Rad Protein Assay Kit according to the
manufacturer’s protocol.
Total proteins (20 μg) or nuclear proteins (10 μg) were separated through SDS-PAGE on a
12% gel and transferred to nitrocellulosemembrane. Blots were incubated with a mouse anti-
Stat1 (1:500, BD Biosciences, Belgium), rabbit anti-phospho-Stat1 (1:1000, Bioke, The Nether-
lands), rabbit anti-p38 (1:1000, Calbiochem, Belgium), rabbit anti-phospho-p38 (1:1000,
Bioke), rabbit anti-ERK (1:20000, Sigma), rabbit anti-phospho-ERK (1:2000, Bioke), mouse
anti-α-tubulin (1:5000, AbCam, UK), rabbit anti-p65 (1:200, Santa Cruz Biotechnologies, Ger-
many), rabbit anti-c-Fos (1:1000, Bioke), rabbit anti-Nrf2 (1:1000, Bioke) and mouse anti-
HDAC1 (1:2000, AbCam) antibody. After washing, membranes were incubated with an anti-
rabbit or anti-mouse IgG-HRP antibody (1:2000, Amersham Biosciences,UK). Antibody com-
plexes were detected by using SuperSignalWest Femto Maximum Sensitivity Substrate (Pierce)
on a ChemiDoc™XRS+ System (Bio-Rad).
Reactive Oxygen Species detection
ReactiveOxygen Species (ROS) were detected by the use of the ROS indicator, 6-carboxy-2',7'-
dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA, Life Technologies), which is a
Table 1. Sequencesof the different real-timePCR primers.
Target gene Accessionnumber Sequences
Cxcl10 NM_021274 for: TTCTGCCTCATCCTGCTG
rev: AGACATCTCTGCTCATCATTC
Nos2 NM_010927 for: AGCCCTCACCTACTTCCTG
rev: CAATCTCTGCCTATCCGTCTC
Ptgs2 NM_011198 for: GCCTGGTCTGATGATGTATGC
rev: GAGTATGAGTCTGCTGGTTTGG
Rpl27 NM_011289 for: ACATTGACGATGGCACCTC
rev: GCTTGGCGATCTTCTTCTTG
Tnf NM_013693 for: GGTTCTGTCCCTTTCACTCAC
rev: TGCCTCTTCTGCCAGTTCC
doi:10.1371/journal.pone.0162717.t001
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chemically reduced, acetylated form of fluorescein. By the activity of ROS within cells, this
non-fluorescent probe was converted to a green-fluorescentmolecule. The 2-methyl-
1,4-naphthoquinone (menadione, 10 μM) was used as a positive control for ROS generation.
This compound generates intracellular ROS (superoxide anions, hydrogen peroxide) at multi-
ple cellular sites through redox cycling.
Microglial cells were plated on poly-L-lysine coated coverslips. As previously described (see
ImmunocytochemistrySection), cells were then fixed after treatments with paraformaldehyde
(4%) and permeabilized.After a blocking step, cells were incubated with a rabbit anti-Iba1
(1:300). After washing steps, cells were incubated with Cy3-conjugated anti-rabbit (1:1000,
Jackson Immuno-Research, UK). Cells were washed and then mounted with Dapi-Fluoro-
mount G. The observationwas performed under a LSM 510 META inverted confocal micro-
scope (Carl ZeissMicro Imaging, Göttingen, Germany) at a 40-fold magnification.
GSH/GSSG ratio determination
Intracellular levels of reduced (GSH) and oxidized (GSSG) glutathione were determined after
treatments in microglial cultures using the luminescence-basedGSH/GSSG-GloTM assay (Pro-
mega). Cells were seeded on 12-well plates at an initial density of 7 x 105 cells/well. According
to the manufacturer’s protocol, intracellular glutathione levels were measured and quantified
using a GSH standard curve. Luminescence was measured using a microplate reader (FLUOs-
tar OPTIMA, BMG Labtech, Offenburg, Germany).
Statistical analysis
Data are represented as mean ± standard error of the mean (SEM) from at least three indepen-
dent experiments. As normality could not be assessed on such samples, multiple group com-
parisons were made using a nonparametric analysis of variance (Kruskal-Wallis test) followed
by pairwise comparisons with Dunn’s correction. All statistical analyses were performed using
GraphPad Prism software and differences with p values less than 0.05 were considered
significant.
For PCR arrays, the HTqPCR package of bioconductor (R packages dedicated to biology)
was used to complete the analysis. One of the HTqPCR data analysis allowed to tag Ct value as
« OK », « undetermined » (Ct value above 35) or « unreliable » (Ct value outside the expected
distribution, computed by HTqPCR) for each sample. Samples with less than 75% of value
tagged as « OK » were removed from the dataset. Four normalization strategies (quantile, rank
invariant, rank invariant scaled, and geometricmean) were applied to the data. Visual inspec-
tion of the normalization result through boxplot and comparison of two dispersionmeasures
(coefficient of variation and standard deviation) lead to choose the quantile method to normal-
ize data. The differentially expressed genes (DEG) list was generated using the Limma package.
The DEG were selectedwhen adjusted p value (Benjamini-Hochberg correction)< 0.05 and
fold changes 2 criteria have been applied.
Results
Activation of microglial cells after α-synuclein proteins exposure
MTT and LDH assays were used to determine changes in viability following exposure of pri-
marymouse microglia to α-synuclein preparations, LPS and other treatments. No loss of via-
bility occurred (data not shown).
In this work, microglial cultures were exposed to the wild-typeα-synuclein protein (WT, α-
syn) as well as to three α-synuclein mutants (A53T, A30P and E46K). Based on LAL assays, no
A53T Protein Induces a StrongMicrogliosis
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endotoxin contamination was detected in our different α-synuclein preparations. First of all,
western-blot analysis (Fig 1) allowed us to visualize the size of these proteins. The different
preparations contained exclusively monomer and dimer bands (respectively 15 and 30 kDa).
The quantity of monomers of these four preparations was similar. Compared toWT and E46K
preparations, which had equivalent amounts of dimers, the proportion of dimers was strongly
lower in A30P (3-fold) and to a lesser extent in A53T preparation (2-fold).
To scale the α-synuclein protein effects,microglial cells were exposed to the pro-inflamma-
tory compound (LPS, 1 ng/ml) for 6 h. The effects of the different proteins on microglia activa-
tion were first established by the changes of microglialmorphology as observedby
immunocytochemistry(Fig 2A). The microglial cell area (Fig 2B) was strongly increased after a
LPS exposure (+ 62% compared to control condition) but also with the A53T peptide (+ 96%)
and at a lower level with the A30P (+ 49%). Furthermore, no modification of morphologywas
observedwith the wild-typeα-syn protein (WT) and the E46Kmutant. No significant change
of cellular proliferation was observed in all these conditions (data not shown).
The effects of α-synuclein proteins exposure for 6 h were also assessed on pro-inflammatory
gene expressions in microglial cells by real-time PCR (Fig 3A). Transcription levels of Tnf,
Cxcl10 and Ptgs2were strongly increased after a LPS exposure as well as after an A53T treat-
ment. An A30P exposure was able to significantly increase Tnf and Ptgs2mRNA levels, but no
significantmodificationwas observedon the Cxcl10 expression. The wild-type protein signifi-
cantly increasedTnf and Cxcl10 expression but at lower levels than after an A53T treatment.
Moreover, an E46K exposure did not promote the up-regulation of these pro-inflammatory
genes. As a result of Tnf and Cxcl10 gene up-regulation, TNFα and CXCL10 releases increased
Fig 1. Analysis of α-synuclein preparations.Representative Western Blot of α-synuclein proteins (wild-
type andmutants) separated by a 12% non-denaturing gel electrophoresis and probedwith monoclonal
antibody 4D6.Wild-type α-synuclein (WT), A53T, A30P and E46Kmutant proteinswere prepared at 2 μM.
L = Ladder (kDa).
doi:10.1371/journal.pone.0162717.g001
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Fig 2. α-synuclein proteins alter differently themicroglial cell morphology. Primary microglial cells were treated for 6 h with the pro-
inflammatory compound LPS (positive control, 1 ng/ml), as well as with 5 μMof the wild-typeα-synuclein (WT) and the 3 mutants (A53T, A30P,
A53T Protein Induces a StrongMicrogliosis
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significantly after 6 h of treatments (Fig 3B). A53T and A30P proteins similarly induced TNFα
release whereas the CXCL10 release was higher after an A53T treatment than after an A30P
exposure. TheWT α-syn was not able to promote the release of TNFα but slightly increased
the CXCL10 secretion. As observed at the mRNA expression levels, E46K was also not able to
increase TNFα and CXCL10 levels in our conditions. Finally, the production of these pro-
inflammatory proteins was lower after α-synuclein protein exposure than after a pro-inflam-
matory treatment (LPS).
Based on these results, the A53T protein appears to be a more potent activator compared to
the other α-synuclein forms. This is why we decided to evaluate the A53T protein effects on
additional pro-inflammatory cytokines / chemokines expression levels by PCR arrays. After an
A53T exposure, 19 genes among the 84 assessed were noticed as significantly overexpressed
(S1 Fig). Tnf and Cxcl10mRNA overexpression was confirmed, and the Cxcl9 chemokine
appeared to be the most up-regulated gene after an A53T exposure.
A53T protein promotesROS production in microglial cells
The carboxy-H2DCFDA probe allowed visualization of intracellular reactive oxygen species
(ROS) production (Fig 4). To evaluate the A53T protein-induced ROS production, microglial
cells were exposed to menadione, a reactive oxygen generator. After 2 h of A53T exposure,
microglial cultures were able to produce reactive oxygen species as shown by the increase of
the intracellular green fluorescence. In these conditions, we also observed a significant decrease
of the GSH/GSSG ratio at 24 h of treatment (Table 2) whereas no effect was observed at 6 h of
treatment.
Implication of JAK-STAT andMAPK signaling pathways in the A53T-
inducedmicroglial reactivitymechanism
In order to dissect the mechanisms underlying the A53T-induced microgliosis, total proteins
were extracted after 30 min, 1 h, 3 h and 6 h of A53T exposure (Fig 5A and 5B). In these condi-
tions, Stat1, p38 and ERK protein expressions were detectable and remained unchanged. Phos-
pho-Stat1 (pStat1) expression was detected at 3 h of treatment and decreased at 6 h. As soon as
30 min of A53T treatment, phospho-p38 (pp38) and phospho-ERK (pERK) were overex-
pressed. These pp38 and pERK expressions decreased over time but appeared as still being up-
regulated at respectively 6 h and 1 h. The expression of phospho-JNK (pJNK), another major
actor of MAPK pathway, was not modulated in these conditions (data not shown). Based on
these results, MAPK signaling appeared to be implicated in the inflammatory state induced by
the A53T protein (Fig 5). We used subsequently different MAPK inhibitors (Fig 6) in order to
confirm the implication of p38 (SB203580, SB), ERK (PD98059, PD) or JNK (SP600125, SP).
The p38 and ERK inhibitors strongly decreased in the same manner the A53T-induced Nos2
and Tnf overexpression by respectively 2.3-fold and 2.5-fold (Fig 6A). Contrary to the ERK
inhibitor, the p38 inhibitor was able to significantly reduce the up-regulation of A53T-induced
Ptgs2 expression (2.1-fold). The JNK inhibitor had no effect on Nos2, Tnf and Ptgs2 up-regula-
tion. Moreover, none of theseMAPK inhibitors were able to significantlymodulate the up-reg-
ulation of Cxcl10mRNA expression. At the protein level (Fig 6B), p38 and ERK inhibitors
E46K) preparations (Fig 2A). Cells were labeledwith themicroglialmarker Iba1 (green) and counterstained with nuclear stain DAPI (blue).
Scale bar: 25 μm. After these treatments,microglial cell area (μm2) was measured (Fig 2B) with the open source image-processing package
Fiji1 software. Data representmean ± SEM of 20 measures per condition. ** p < 0.01, *** p < 0.001, significantly different from control
condition.
doi:10.1371/journal.pone.0162717.g002
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Fig 3. α-synuclein proteinsmodulatedifferently pro-inflammatory gene expressions as well as pro-inflammatorymediator releases.
Following exposure of primarymousemicroglial cells to LPS (1 ng/ml) and α-synuclein proteins (WT andmutants, 5 μM) for 6 h, pro-inflammatory
A53T Protein Induces a StrongMicrogliosis
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strongly reduced TNFα, CXCL10 and PGE2 releases by respectively 2.2-fold, 6-fold and
2.9-fold. The JNK inhibitor had no effect on the A53T-induced TNFα and PGE2 releases but
reduced by 2.7-fold the CXCL10 production.
Involvement of the NFkB, AP-1 and Nrf2 pathways in the A53T-induced
microglial reactivitymechanism
The two transcription factors, NFkB and AP-1, are known to be implicated in numerous
inflammatory states. The nuclear factor (erythroid-derived2)-like 2 (Nrf2) regulates cellular
responses against oxidative and inflammatory stress. Therefore, NFkB, AP-1 and Nrf2 were
investigated and quantified (Fig 7A and 7B). The effectiveness of the nuclear isolation was also
verified (Fig 7C). Nuclear proteins were extracted after 30 min, 1 h and 2 h of A53T exposure
(Fig 7A and 7B). After 30 min, NFkB activation was detected in microglial cells, evidencedby
the nuclear localization of p65. This NFkB activation decreased over time but was still observed
at 1 h and 2 h of treatment. Likewise,AP-1 activation was observed in our conditions by an
increase of c-Fos subunit in the nucleus. Compared to NFkB activation, the AP-1 recruitment
took place later, at 1 h and decreased at 2 h of A53T exposure. Furthermore, no detectable Nrf2
nuclear translocation could be observed in microglial cultures after 30 min and 1 h of A53T
treatment, but only at 2 h of treatment. The decrease of the transcription factors recruitment
coincidedwith a time-dependent decrease of the pro-inflammatory gene overexpression (S2
Fig).
Discussion
Evidences of an ongoing inflammatory state in Parkinson’s disease come from studies showing
increased pro-inflammatorymolecules levels in the blood and cerebrospinal fluid (CSF) in
patients [35,36]. Indeed, it is now well documented that pro-inflammatorymolecules (cyto-
kines, chemokines, prostaglandins) and reactive oxygen species are associated with neurode-
generation and particularly with Parkinson’s disease pathogenesis progression [37,38]. PD is
histologically describedby the deposition of α-synuclein and as a result by the accumulation of
protein aggregates called Lewy bodies. Althoughmost PD cases are sporadic, point mutations
of the gene encoding the α-synuclein protein, cause inherited forms of PD.
Microglia are known to react rapidly and strongly to brain insults. These cells are clearly
recognized as a principal player for neuroinflammation in the central nervous system [39,40].
In this work, based on in vitro experiments on primarymurine microglia, we have established
that microglia activation intensity appears to be α-synuclein protein-dependent. Indeed, the
wild-typeα-synuclein (WT α-syn) and the 3 correspondingmutants (A53T, A30P and E46K)
differentially activate microglial cultures. Recent works have been published on the degree of
α-synuclein-mediated toxicity, with regard to the conformation of the protein [4]. Here, we
focussed our attention on monomers and dimers of α-synuclein that might correspond to an
early stage of PD pathology.
This study is based on recombinant α-synuclein proteins. It is generally assumed that
endogenous α-synuclein involved in Parkinson’s diseasemay be subject to post-translational
gene expressions (Tnf,Cxcl10 and Ptgs2) were analyzed by real-time PCR (Fig 3A). Control expression levels were fixed at 1.0. All gene
expressions were normalized to Rpl27 expression level. Results are given as mean ± SEM (n = 4 independent experiments). TNFα and CXCL10
protein releases (Fig 3B) were quantified by ELISA in supernatantof microglial cultures after 6 h of LPS (1 ng/ml) and α-synuclein proteins (5 μM)
treatment.Results are given as mean ± SEM (n = 4 independent experiments). * p < 0.05, ** p < 0.01, *** p < 0.001, significantly different from
control condition.
doi:10.1371/journal.pone.0162717.g003
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Fig 4. A53T protein promotes ROS production.Primarymicroglial cells were treated for 2 h with the A53T protein (5 μM)
as well as with a reactive oxygen generator (menadione, 10 μM). After treatments, cells were incubated for 20 min with the
6-carboxy-2',7'-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA, 2 μM) probe. This nonfluorescent probewas
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modifications (phosphorylation, oxidation, nitrosylation, glycation or glycosylation) [41,42].
These modifications could strongly modify the pathogenic properties of the disease-associated
proteins. This is not the case for recombinant proteins. Thus, a disparity of microglial activa-
tion could appear when comparing endogenous and recombinant α-synuclein exposure. A spe-
cial care should be taken before issuing conclusions.
In the presence of recombinant α-synuclein proteins, our data showed an increase of the
pro-inflammatory state. Indeed, after only 6 h of treatment, A53T and A30P mutants were able
to modifymicrogliamorphology, unlikeWT α-synuclein and E46K exposures. Furthermore,
the A53T mutant was also able to strongly overexpress Tnf, Cxcl10 and Ptgs2mRNA levels,
whereasWT α-syn or A30P only show a weak up-regulation of these pro-inflammatory genes.
These mRNA expression level modulations confirm our data on cell morphology. TNFα and
CXCL10 releases (Fig 3B) corroborate our pro-inflammatory gene expression analyses (Fig
3A). Furthermore, compared to a pro-inflammatory positive control (LPS treatment), an A53T
exposure increases more weakly mRNA and protein expression levels. Finally, the A53T pro-
tein promotes a more pronounced pro-inflammatory phenotype on primarymicroglia and
appears to be a more potent activator compared to the A30P mutant and the wild-typeα-synu-
clein. The E46K protein has no effect on microglial activation (A53T> A30P>WT> E46K).
These results are in accordance with other studies that have described a higher pro-inflamma-
tory potential of the α-synuclein mutant proteins compared to the wild-type protein [43–45].
Data from the literature also describe that microglial cell lines often respond differently to
pathological stimuli (e.g. synuclein or beta-amyloid protein) [46,47] and confirm the impor-
tance of working on primary cultures.
The conformation of the α-synuclein protein (monomers / oligomers / fibrils), responsible
for toxicity in PD, is still not clear. Several works have describedhigher cytotoxicity of the solu-
ble oligomers compared to fibrils [12,48,49]. However, many recent reports have described
that α-syn fibrils could be toxic by inducing apoptotic cell death [50,51]. In our conditions, α-
synuclein proteins are composed of monomers and dimers. Interestingly, WT and E46K pro-
teins, the two preparations with more dimeric fragments (30 kDa), exhibit a less strong micro-
glial reactivity compared to A53T and A30P. Moreover, the fact that these cells react more
strongly to the presence of mutated α-synuclein, could lead to an earlier onset and faster pro-
gression of the pathology, as observedduring familial PD forms [52,53]. Due to the composi-
tion of our α-synuclein preparations, it is important to note that the specific involvement of
monomers, or dimers, on microglial reactivity could not be clearly determined. In additional
converted to a green-fluorescent form by the activity of ROS within cells. Cells were also labeledwith themicroglialmarker
Iba1 (red) and counterstained with nuclear stain DAPI (blue). Scale bar: 50 μm.
doi:10.1371/journal.pone.0162717.g004
Table 2. An A53T exposure affects theGSH/GSSG balance. Primarymicroglial cells were treated for 6 h and 24 h with the A53T protein (5 μM) as well as
with a reactive oxygen generator (menadione, 10 μM). After treatments, intracellular levels of reduced (GSH) and oxidized (GSSG) glutathionewere mea-
sured. The ratio GSH/GSSGwas established as a marker of oxidative stress. Results are given as mean ± SEM (n = 4 independent experiments).
GSH/GSSG (6h) GSH/GSSG (24h)
Mean (% of control) SEM Mean (% of control) SEM
Control 100.0 10.6 100.1 6.4
Menadione 109.1 3.5 82.9 * 3.9
A53T 106.2 3.4 74.6 * 3.0
* p < 0.05, significantly different from control condition.
doi:10.1371/journal.pone.0162717.t002
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experiments, we have also established that mutated proteins could have a higher ability to
aggregate compared to the wild-typeα-synuclein protein (data not shown). Using these recom-
binant proteins, it would be important to perform further experiments in order to verify the
direct impact of monomers, dimers, as well as larger α-synuclein samples (oligomers, proto-
fibrils, fibrils) on microglial reactivity.
A53T, A30P and E46Kmutants, as well as wild-typeα-synuclein, are natively unfolded
under physiological conditions [17,54]. Sahay and collaborators described that the overall
structure of the α-syn protein is not affected by these mutations [55]. However, A53T, A30P
and E46K proteins present mutations in the N-terminal part of the α-synuclein protein. This
N-terminal amphipathic region is important for α-synuclein functions and membrane interac-
tions [56,57] as well as for macrophage activation [58]. Microglial cells are known to react to
the presence of foreign substances by the expression of receptors called pattern recognition
receptors (PRRs) on the cell surface. These PRRs include Toll-like receptors (TLRs), receptor
for advanced glycation end products (RAGE) and scavenger receptors [59–61]. Ligation to
PRRs triggers a succession of cellular signaling events, including the activation of signal trans-
duction pathways [62–66]. Thus, a modification of the N-terminal region of the α-synuclein
proteins may disrupt or facilitate the recognition and the binding of the protein on the micro-
glial cell surface and consequently may modulate the activation of signaling pathways.
The signal transduction of the A53T protein-induced microglial reactivity was subse-
quently evaluated. First of all, the A53T protein was found to activate microglia in a time-
dependent (S2 Fig) but also in a dose-dependentmanner (S3 Fig). Then, by western-blot
analyses, we have highlighted the activation of the Stat1 protein by the presence of phosphor-
ylated Stat1 (pStat1) after an A53T exposure. The overexpression of pStat1, a marker
expressed by reactive microglia, confirms the establishment of a pro-inflammatory state in
these experimental conditions. We have also demonstrated the recruitment of activated p38
and ERKMAPKs, but no modulation of the JNK pathway has been revealed. Indeed, the use
of MAPK inhibitors strongly decreases the A53T-induced microglial reactivity by reducing
pro-inflammatory gene overexpression but also pro-inflammatorymolecule releases. These
results confirm that p38 and ERKMAPKs are implicated in the A53T-induced microglial
activation. In the literature, in vitro and in vivo experiments confirm the implication of pro-
tein kinases in glial cells in neurodegenerative diseases [47,67]. ERK activation has also been
described to act downstream of Stat signaling during microglial activation [68,69] and there-
fore confirms our results.
In this work, the A53T-induced microglial reactivity is associated with the recruitment of
the NFkB, AP-1 and Nrf2 transcription factors. It is well established that many pro-inflamma-
tory genes contain functional NFkB and/or AP-1 response elements. Our data on nuclear pro-
tein extracts reveal the recruitment of p65 (a NFkB subunit) in a time-dependentmanner with
a maximum reached after 30 min. The A53T protein also increases c-Fos (an AP-1 subunit)
protein levels with a peak expression after 1 h of treatment. Several studies confirm our find-
ings [70–72]. In many cell types, NFkB and AP-1 activities are known to beMAPK-dependent
Fig 5. A53T protein inducesSTAT1 phosphorylation andMAPKs activation.After 30 min, 1 h, 3 h or 6 h of A53T
protein exposure (5 μM),microglial cell lysates were subjected to western-blot analysis (Fig 5A) to determine the
expression of phospho-Stat1 (pStat1), phospho-p38 (pp38) and phospho-ERK (pERK).α-Tubulin (αTub) was used
as a loading control. These chemiluminescent detection assays were realized with 20 μg of total proteins. Ratios
between phosphorylatedversus non-phosphorylatedproteins, called pStat1/Stat1, pp38/p38 and pERK/ERK, were
described in Fig 5B. Results are given as mean ± SEM of at least three independent experiments. * p < 0.05,
significantly different from control condition.
doi:10.1371/journal.pone.0162717.g005
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[47,73–75]. On the one hand, the NFkB activation has been shown to beMAPK-dependent by
the phosphorylation of the NFkB inhibitory protein IkB [76,77]. On the other hand, AP-1 sub-
units have also been described to be phosphorylated by MAPKs on specific sites that strengthen
their transcriptional activities [78].
A battery of genes encoding detoxification enzymes also contains antioxidant response ele-
ment (ARE) sequences. This ARE is activated through the binding of its transcription factor,
Nrf2. The Nrf2-ARE pathway is known to regulate the cell response against oxidative and
inflammatory stress [79]. Lastres-Becker and collaborators have demonstrated that Nrf2 was
able to modulate microglial reactivity [80]. The Nrf2 pathway is the major regulator of cytopro-
tective responses to endogenous and exogenous stresses caused by reactive oxygen species
(ROS). In our conditions, an A53T exposure is able to increase the production of ROS after 2 h
of treatment. The Nrf2 recruitment, after 2 h of A53T exposure, coincides with this increase of
ROS production by microglia. Likewise, we have determined that an A53T exposure for 24 h
was able to decrease the microglial GSH/GSSG ratio due to an increase of the GSSG level con-
sequently to a ROS-inducedGSH oxidation.
In summary, this work provides a good description of how the presence of A53T mutant
protein can rapidly and strongly activates microglial cells by a mechanism in whichMAPKs,
NFkB, AP-1 and Nrf2 transcription factors are engaged. Our data suggest that NFkB and AP-1
activation are early and direct events of A53T signaling. The Nrf2 activation may be a second-
ary event that participates in both reducing ROS production but also providing a negative feed-
back control of inflammation [80–82]. The pro-inflammatory profile acquired by microglial
cells, highlighted by our data, confirm the existence of a vicious circle that happens during PD
progression [83]. These results are in accordance with the hypothesis that in early stages of PD,
small diffusibleα-synuclein proteins activate microglia leading to an inflammatory state [25].
Inflammatory stimuli, together with persistent microglial activation, perpetuate an activated
state that potentiates neuronal death. More precisely, activation of microglia and release of
numerous pro-inflammatory compounds play important roles in dopaminergic neuronal
death in the substantia nigra, leading notably to the release of ATP but also of α-synuclein pro-
teins, which again can both stimulate microglia [39,71,84].
The role of microglial cells in Parkinson’s disease remains still complex and unclear. How-
ever, our results reinforce the hypothesis that controlling neuroinflammatorymechanisms
appear to be a useful strategy to contain PD progression. Therefore, these findingsmay be rele-
vant to neurodegenerative diseases involving inflammation, but also to aging where brain
metabolism can be deeply altered. Like in other neurodegenerative diseases, aging is one of the
most significant risk factor for PD. Recently, Bliederhaeuser and collaborators have highlighted
that age-related microglial alterations (increase of the inflammatory status, decrease of the
phagocytic activity and of the antioxidant defenses) may contribute to an increased susceptibil-
ity to pathogens or abnormally folded proteins in neurodegenerative diseases [85]. Further
studies are needed to fully understand the underlyingmechanisms of dysregulatedmicroglia
with aging and their contribution to the progression of PD.
Fig 6. MAPKs are implicated in the A53T-inducedmicroglial reactivity. Primarymousemicroglial cell cultures
were pre-treated for 1 h with 10 μMp38 inhibitor (SB203580, SB), ERK inhibitor (PD98059, PD) or JNK inhibitor
(SP600125, SP) before the addition of A53T protein (5 μM) for 6 h. Pro-inflammatory gene expressions (Nos2, Tnf,
Ptgs2,Cxcl10) were analyzed by real-time PCR (Fig 6A). Control expression levels were fixed at 1.0. All gene
expressions were normalized to Rpl27 expression level. Results are given as mean ± SEM (n = 5 independent
experiments). Pro-inflammatorymediators released in the supernatantof microglial cultures (Fig 6B) were
quantified by ELISA (TNFα, CXCL10) or EIA (PGE2). Results are given as mean ± SEM (n = 5 independent
experiments). * p < 0.05, ** p < 0.01 significantly different from control condition; § p < 0.05 significantly different
fromA53T-treated cells.
doi:10.1371/journal.pone.0162717.g006
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Supporting Information
S1 Fig. A53T protein up-regulatesmany pro-inflammatorygene expressions. Pro-inflam-
matory gene expression levels were analyzed by PCR arrays after 6 h of A53T exposure (5 μM).
PCR arrays (RT2 Profiler™ PCR Array Mouse Cytokines & Chemokines, Qiagen, The Nether-
lands) were performed on 1 μg of total RNA per array plate and allowed to assess 84 different
genes simultaneously. The differentially expressed genes after the A53T stimulation were listed
when the criteria fold changes> 2 and p value< 0.05 have been applied. Control expression
levels were fixed at 1.0. All gene expressions were normalized to housekeeping genes expression
level. Results are given as mean ± SEM (n = 3 independent experiments).
(TIF)
S2 Fig. The A53T exposure-inducedmicrogliosis decreasesover time. Pro-inflammatory
gene expressions (Nos2, Tnf and Ptgs2) were analyzed by real-time PCR following exposure of
primarymouse microglial cells to A53T protein (5 μM) for 6, 24 and 48 h. Control expression
levels were fixed at 1.0. All gene expressions were normalized to Rpl27 expression level. Results
are given as mean ± SEM (n = 3 independent experiments).
(TIF)
S3 Fig. A53T protein modulates pro-inflammatorygene expressions as well as pro-inflam-
matorymediators in a concentration-dependentmanner. Following exposure of primary
mouse microglial cells to different concentrations of A53T protein for 6 h, pro-inflammatory
gene expressions (Nos2, Tnf, Ptgs2 and Cxcl10) were analyzed by real-time PCR (S3A Fig).
Control expression levels were fixed at 1.0. All gene expressions were normalized to Rpl27
expression level. Results are given as mean ± SEM (n = 3 independent experiments). In these
conditions, pro-inflammatorymediators released in the supernatant of microglial cultures
were quantified by ELISA (S3B Fig). Results are expressed as fold increase compared to control
and are given as mean ± SEM (n = 3 independent experiments).  p< 0.05,  p< 0.01, signifi-
cantly different from control condition.
(TIF)
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